where to next?, page-902

His resume has a number of unique qualities that suggest he is worth the money. More than anything, think of his salary in context of the the statement below - taken from poison.org

The opioid epidemic has evolved rapidly in recent years, starting with an increase in opioid prescriptions to treat chronic pain. To reduce risk and maximize the benefits of pain treatment options, the CDC issued guidelines for opioid prescribing. The guidelines recommend non-opioid medications as the preferred first step when treating chronic pain.

Big pharma is under increasing pressure to address this issue globally. His previous position at Teva is clearly a massive advantage to AusCann in this regard.
Leveraging just a fraction of his deep connections could be a game changer.